• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies.

作者信息

Vendramin Chiara, Thomas Mari, Westwood John-Paul, McGuckin Siobhan, Scully Marie

机构信息

Department of Haematology, University College London Hospital, London, UK.

Department of Haematology, University College London Hospital, Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, UK.

出版信息

Br J Haematol. 2019 Mar;184(5):858-861. doi: 10.1111/bjh.15177. Epub 2018 Mar 12.

DOI:10.1111/bjh.15177
PMID:29527657
Abstract
摘要

相似文献

1
Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies.
Br J Haematol. 2019 Mar;184(5):858-861. doi: 10.1111/bjh.15177. Epub 2018 Mar 12.
2
[Acquired thrombotic thrombocytopenic purpura with rituximab-induced serum sickness].[获得性血栓性血小板减少性紫癜合并利妥昔单抗诱导的血清病]
Rinsho Ketsueki. 2024;65(10):1265-1269. doi: 10.11406/rinketsu.65.1265.
3
Rituximab-Induced Serum Sickness-Like Reaction: A Histopathologic Viewpoint.利妥昔单抗诱导的血清病样反应：组织病理学观点
Am J Dermatopathol. 2016 Apr;38(4):321-2. doi: 10.1097/DAD.0000000000000356.
4
The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.奥滨尤妥珠单抗和奥法妥珠单抗在免疫性血栓性血小板减少性紫癜治疗中的应用。
Br J Haematol. 2022 Jul;198(2):391-396. doi: 10.1111/bjh.18192. Epub 2022 Apr 17.
5
Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab.奥滨尤妥珠单抗治疗两名对利妥昔单抗不耐受的免疫介导性血栓性血小板减少性紫癜患者。
Am J Hematol. 2019 Oct;94(10):E259-E261. doi: 10.1002/ajh.25583. Epub 2019 Aug 9.
6
Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies.病例报告：在利妥昔单抗诱导的血清病和抗利妥昔单抗抗体合并难治性免疫性血小板减少症的患者中，使用奥滨尤妥珠单抗作为替代单克隆抗 CD20 抗体。
Front Immunol. 2022 Apr 19;13:863177. doi: 10.3389/fimmu.2022.863177. eCollection 2022.
7
Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.利妥昔单抗诱导的难治性免疫性血小板减少性紫癜血清病。
Intern Med J. 2011 Feb;41(2):202-5. doi: 10.1111/j.1445-5994.2010.02384.x.
8
Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.免疫介导的血栓性血小板减少性紫癜的强化利妥昔单抗方案可避免对标准利妥昔单抗治疗无反应。
Br J Haematol. 2021 Jan;192(1):e21-e25. doi: 10.1111/bjh.17170. Epub 2020 Nov 20.
9
Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.利妥昔单抗治疗难治性特发性血小板减少性紫癜（ITP）和血栓性血小板减少性紫癜（TTP）：三例报告
Am J Hematol. 2005 Jan;78(1):49-54. doi: 10.1002/ajh.20243.
10
[Response to rituximab in two patients with plasma exchange-refractory thrombotic thrombocytopenic purpura].[两名血浆置换难治性血栓性血小板减少性紫癜患者对利妥昔单抗的反应]
Med Clin (Barc). 2011 Jun 25;137(3):139-40. doi: 10.1016/j.medcli.2010.07.020. Epub 2010 Nov 11.

引用本文的文献

1
How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance.利妥昔单抗治疗失败或不耐受后，我们如何管理免疫介导的血栓性血小板减少性紫癜。
Br J Haematol. 2025 Jun;206(6):1560-1570. doi: 10.1111/bjh.20101. Epub 2025 Apr 24.
2
Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.获得性免疫性血小板减少性紫癜（iTTP）的管理：急性期之后
Ther Adv Hematol. 2022 Jul 26;13:20406207221112217. doi: 10.1177/20406207221112217. eCollection 2022.
3
Anti-CD20 therapeutic options in immune-mediated thrombotic thrombocytopenic purpura.
免疫介导性血栓性血小板减少性紫癜的抗 CD20 治疗选择。
Br J Haematol. 2022 Jul;198(2):225-226. doi: 10.1111/bjh.18215. Epub 2022 Apr 26.
4
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?利妥昔单抗治疗多发性硬化症：我们是否已准备好监管批准？
Front Immunol. 2021 Jul 6;12:661882. doi: 10.3389/fimmu.2021.661882. eCollection 2021.
5
Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.儿童激素依赖型肾病综合征中的抗利妥昔单抗抗体
Pediatr Nephrol. 2022 Feb;37(2):357-365. doi: 10.1007/s00467-021-05069-w. Epub 2021 Jun 16.
6
Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.无反应性血栓性血小板减少性紫癜（TTP）：挑战与解决方案
Ther Clin Risk Manag. 2021 Jun 3;17:577-587. doi: 10.2147/TCRM.S205632. eCollection 2021.
7
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.奥法妥木单抗治疗合并利妥昔单抗诱导血清病的多复发性膜性肾病
BMJ Case Rep. 2020 Jan 23;13(1):e232896. doi: 10.1136/bcr-2019-232896.
8
Pemphigus: Current and Future Therapeutic Strategies.天疱疮：当前和未来的治疗策略。
Front Immunol. 2019 Jun 25;10:1418. doi: 10.3389/fimmu.2019.01418. eCollection 2019.
9
Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura.利妥昔单抗联合环磷酰胺治疗难治性特发性血小板减少性紫癜的疗效
Exp Ther Med. 2019 Mar;17(3):2137-2142. doi: 10.3892/etm.2019.7196. Epub 2019 Jan 23.